(Q42242398)

19 October 2017

title

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma (English)

1 reference

19 October 2017

1 reference

J. P. Neijt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

W. W. ten Bokkel Huinink

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

M. E. van der Burg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

A. T. van Oosterom

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

R. Vriesendorp

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

C. D. Kooyman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

A. C. van Lindert

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

J. V. Hamerlynck

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

M. van Lent

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

J. C. van Houwelingen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6147640

14 August 2023

language of work or name

English

0 references

publication date

1 September 1984

1 reference

19 October 2017

15 September 1984

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6147640

full work available at URL

14 August 2023

https://api.elsevier.com/content/article/PII:S0140673684905944?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(84)90594-4

https://api.elsevier.com/content/article/PII:S0140673684905944?httpAccept=text/plain

14 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(84)90594-4

14 August 2023

1 reference

19 October 2017

volume

2

1 reference

19 October 2017

issue

8403

1 reference

19 October 2017

page(s)

594-600

1 reference

Hexamethylmelamine: An evaluation of its role in the treatment of ovarian cancer

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

cis-Platinum in gynecologic cancer. I. Epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Second trial drugs in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Management of ovarian carcinoma. Current concepts and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Epithelial carcinoma of the ovary: current strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2884%2990594-4

7 January 2021

Chemotherapy of ovarian cancer: past and present

4

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(84)90594-4

Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma

14 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(84)90594-4

Therapy of advanced ovarian carcinoma

14 August 2023

25

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(84)90594-4

Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease

14 August 2023

30

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(84)90594-4

14 August 2023

Identifiers

1 reference

release_n4re4z2jxbeqper75hmgkzuohi

19 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n4re4z2jxbeqper75hmgkzuohi

24 November 2022

mapped directly with Wikidata item

1 reference